Summary of significant accounting policies (Tables)

12 Months Ended

Jul. 31, 2019

Accounting Policies [Abstract]

Schedule Of Accounts Receivable By Segment [Table Text Block]

The following is a table of the Company’s net accounts receivable by segment.

	July 31, 2019					July 31, 2018
Net accounts receivable by segment	Amount		%			Amount		%
Clinical Labs (by billing category)
Third party payers	$	2,956		44		$	4,692		48
Patient self-pay		2,360		35			2,010		20
Medicare		910		13			1,740		18
HMO’s		574		8			1,329		14
Total Clinical Labs		6,800		100	%		9,771		100	%
Total Life Sciences		3,938					3,376
Total accounts receivable – net	$	10,738				$	13,147

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following table sets forth the computation of basic and diluted net income (loss) per share for the years ended July 31:

	2019		2018			2017
Net income (loss)	$	2,489	$	(10,321	)	$	(2,504	)
Weighted-average common shares outstanding - basic		47,351		46,972			46,350
Add: effect of dilutive stock options and restricted stock		125		—			—
Weighted-average common shares outstanding - diluted		47,476		46,972			46,350
Net (loss) income per share – basic	$	0.05	$	(0.22	)	$	(0.05	)
Net (loss) income per share – diluted	$	0.05	$	(0.22	)	$	(0.05	)

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

The following table sets forth the amount of expense related to share-based payment arrangements included in specific line items in the accompanying statement of operations for the years ended July 31:

	2019		2018		2017
Cost of clinical laboratory services	$	—	$	—	$	6
Selling, general and administrative		939		813		825
	$	939	$	813	$	831

Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]

The impact of the adoption of the standard on prior period consolidated operations, cash flows and balance sheet is presented in the table below:

	As Previously Reported	Adjustment for New Accounting Standard on Revenue Recognition	Reclassification of Residual	As Restated
Consolidated Statements of Operations for fiscal year ended July 31, 2018:
Total Revenues	$104,713	($3,700)	—	$101,013
Provision for uncollectible accounts receivable	3,690	(3,700)	$10	—
Selling, general and administrative expenses	44,465	—	(10)	44,455
Net loss	(10,321)	—	—	(10,321)
Consolidated Statements of Cash Flows July 31, 2018:
Provision for uncollectible accounts receivable	3,690	(3,700)	10	—
Changes in operating assets and liabilities: Accounts receivable	(1,775)	3,700	(10)	1,915
Consolidated balance sheet July 31, 2018:
Accounts receivable	15,815	(2,523)	—	13,292
Less: Allowance for doubtful accounts	2,668	(2,523)	—	145
Accounts receivable, net of allowance for doubtful accounts	13,147	—	—	13,147
Consolidated Statements of Operations for the year ended July 31, 2017:
Total Revenues	$107,804	($2,718)	—	$105,086
Provision for uncollectible accounts receivable	2,775	(2,718)	($57)	—
Selling, general and administrative expenses	44,092	—	57	44,149
Net loss	(2,504)	—	—	(2,504)
Consolidated Statements of Cash Flows July 31, 2017:
Provision for uncollectible accounts receivable	$2,775	($2,718)	($57)	—
Changes in operating assets and liabilities: Accounts receivable	(3,244)	2,718	57	($469)